

Index

- abuse pattern, domestic violence 93–94, 96
- abortion and miscarriage
 - depression 124–125
- aetiology
 - biological variables 141–142
 - biopsychosocial models 145
 - cultural aspects 144–145
 - Dimensional Assessment of Personality Pathology (DAPP) 28
 - psychosocial factors 143–144
 - sex-specific genetic effects 28
- affective disorders, adolescence 1–3
 - gender gap, fact or artefact 2–3
- affective suffering, depression 246
- agoraphobia 61–62, 187, 246
 - childhood\adolescence 62
 - comorbidity 62
- androgens 120
- anticonvulsant
 - pregnancy and lactation
 - carbamazepine 177
 - valproate 176–177
 - BD management in postpartum period
 - carbamazepine 203
 - lamotrigine 203
 - topiramate 203
 - valproate 202–203
 - BD management in pregnancy
 - carbamazepine 195–196
 - lamotrigine 196
 - topiramate 196–197
 - valproate 194–195
- antidepressant
 - anxiety and depression
 - agents, others 174
 - SSRIs 173
 - tricyclic antidepressants 174
 - depression 254–255
- anti-psychotics, first-generation 197, 204
- anti-psychotics, second-generation 197–198, 204
 - see also* novel anti-psychotics
- antisocial personality disorders 41–42
- anxiety
 - anxiolytic drugs 257–258
 - non-pharmacological interventions 258–259
- anxiety and depression, old aged women
 - barriers to care 259–260
 - burden of depression 247–248
 - classification and diagnosis 246–247
 - epidemiology
 - anxiety 245–246
 - depression 245
 - future 260–261
 - management
 - anxiety 257–259
 - depression 252–257
 - primary and secondary prevention 260
 - prognosis 259
 - psychological development, old age 244–245
 - risk and protective factors
 - precipitating factors 250–251

268 Index

- anxiety and depression, old aged women
 - (*contd*)
 - risk and protective factors (*contd*)
 - predisposing factors 248–250
 - protective factors 251
- anxiety and mood disorders
 - detection, screening 145–146
 - during perinatal period 137–138
 - mood in pregnancy 138
 - postpartum mood disorders 138–140
 - postpartum psychosis 140–141
 - pregnancy and postpartum period 136
 - prevention 146–147
 - risk factors/aetiology
 - biological variables 141–142
 - biopsychosocial models 145
 - cultural aspects 144–145
 - psychosocial factors 143–144
 - treatment issues
 - child 151–152
 - inpatient units 149–150
 - mother 147–149
 - partners and couples 150–151
- anxiety disorders
 - in women
 - agoraphobia 61–62
 - generalized anxiety disorder 64–65
 - menstrual cycle, influences 68–69
 - obsessive–compulsive disorder (OCD) 67–68
 - panic disorder 59–60
 - perinatal anxiety disorders 69–70
 - PTSD 62–64
 - social phobia 65–66
 - symptoms, PTSD 63
 - perinatal period 137–138
- anxiolytic drugs
 - benzodiazepines 168–170, 257, 258
 - buspirone 170, 257
 - phenothiazines 257
 - propranolol 170–171
- barriers to care
 - in women, in old age 259–260
- barriers to change, domestic violence
 - detecting 101–102
 - disclosing 103–104
 - identification 102–103
- BD and reproduction
 - childbearing, risk factor 190–191
 - preconception 188–189
 - reproductive health 188
 - untreated BD, childbearing 189–190
- BD, gender differences
 - co-morbidity and gender 187–188
 - onset 186
 - symptoms, illness and treatment 186–187
- benzodiazepine
 - anxiety and depression 168–170
 - neurodevelopmental teratogenicity 169
 - fetal and neonatal effects 198–199
 - therapy, during pregnancy and delivery 199
- biological parameters, substance abuse 42–43
- bipolar affective disorder, women
 - BD and reproduction 188–191
 - childbearing, risk factor 190–191
 - preconception 188–189
 - reproductive health 188
 - untreated BD during childbearing 189–190
 - gender differences, in BD 186–188
 - co-morbidity and gender 187–188
 - onset 186
 - symptoms, illness and treatment 186–187
- postpartum period, management of BD 200–204
 - anti-convulsants 202–203
 - anti-psychosis 204
 - BDPs 204
 - breastfeeding and medication 201–202
 - lithium 202
 - postpartum psychosis 200–201
 - treatment, postpartum psychosis 201

269 Index

- pregnancy, management of BD, 191
 - anti-convulsants 194–197
 - anti-psychotics 197–198
 - benzodiazepines 198–199
 - electroconvulsive therapy 199
 - lithium 193–194
 - principle 191–192
- bipolar disorder (BD) 185
- borderline personality disorder (BPD)
 - sex differences
 - aetiology 27–29
 - clinical presentation 25–26
 - diagnostic features 20–21
 - longitudinal course 26–27
 - neurobiology 29–31
 - sources 21–24
 - temporal stability 26–27
- burden of depression 247–248
- bupirone 170
- carbamazepine
 - anticonvulsants
 - anxiety and depression 177–178
 - bipolar affective disorder 195–196, 203
- child
 - development 151–152
 - obstetric outcomes 151
 - effects of domestic violence 100–101
- climacteric 213, 223
- clinical and service recommendations
 - domestic violence
 - intervention 105–106
 - inter-agency collaboration 106–107
 - raising awareness 104–105
 - training 105
- clinical implications, mood and menopause 234
- clinical presentation
 - childhood sexual abuse (CSA) 25, 29
 - externalising pathology, males 25–26
 - internalising pathology, females 26
- cognitive behaviour therapy (CBT) 147, 254, 256, 259
- communication barriers
 - mood disorders
 - detecting domestic violence 101–102
- Cornell Depression Rating Scale 252
- cortisol and thyroid hormones 118
- cross-sectional studies, results
 - mood and menopause 216–225
- culture/race
 - effect, MT 215–216
 - Study of Women’s Health Across the Nation (SWAN) 216
- depression
 - antidepressants 254–255
 - assessment 252–253
 - gonadal hormonal influences 118–120
 - psychological and psychotherapeutic interventions 255–257
 - resistant depression 257
 - and suicide 97–98
 - treatment principles 253–254
- depression and menopause
 - methodological aspects of study
 - Centre for Epidemiological Studies Depression scale (CES-D) 215
 - limitations 215
- depression and suicide 97–98
- depression in women, hormonal influences
 - epidemiology 116–118
 - gonadal hormonal influences
 - androgens 120
 - oestrogen 118–120
 - progesterone 120
- specific life cycle, depressive disorders
 - abortion and miscarriage 124–125
 - hormonal contraception 122–124
 - infertility and depression 128–129
 - perimenopause, menopause and depression 129–130
 - PND 125–128
 - pregnancy and depression 125
 - premenstrual dysphoric disorder 121–122

270 Index

- detecting domestic violence
 - communication barriers
 - mood disorders 101–102
- detection, screening
 - perinatal depression 145–146
- diagnostic features
 - categorical approach 20–21
 - criteria 20
- disclosing domestic violence 103–104
- domestic violence
 - abuse pattern 93–94
 - clinical and service recommendations 104–107
 - detecting 101–102
 - disclosing 103–104
 - effects on children 100–101
 - identification 102–103
 - incidence and prevalence 93
 - mental health outcomes
 - depression and suicide 97
 - PTSD and anxiety disorder 98
 - risk predictor
 - child abuse 96
 - pregnancy 94–96
 - substance misuse 99–100
- Edinburgh postnatal depression scale (EPDS) 139, 146
- education
 - psychosocial factors 143
- electroconvulsive therapy (ECT) 149, 199, 257
- emergence of gender gap, theories
 - gender intensification hypothesis 3–5
 - limitations 5–7
 - gender roles and individual differences
 - personality 7–8
 - pubertal change
 - and interpersonal stressors 9–10
 - pubertal development and diathesis
 - affective disorder 8–9
- endocrine changes, menopause
 - dehydroepiandrosterone sulphate (DHEAS) 214
 - Melbourne Women’s midlife Health Project
 - follicle stimulating hormone (FSH) 214
- epidemiology
 - anxiety 245–246
 - depression 245
 - premenopausal women 117
 - gonadal steroids 118
 - neuropsychiatric disorders 116
- epidemiology and clinical issues
 - comorbidity and long-term course 41–42
 - course worse, women
 - biological parameters 42–43
 - psychosocial issues 43–44
 - substance use and abuse
 - gender differences 39–41, 43
- fetal and neonatal effect, BD
 - benzodiazepines 198–199
 - carbamazepine, anti-convulsants 195
 - first generation anti-psychotics 197
 - lamotrigine, anti-convulsants 196
 - lithium, BD management 193
 - second generation anti-psychotics 197–198
 - valproate, anti-convulsants 194–195
- fitness-enhancing goals 13
- floppy infant syndrome 169
- foetal alcohol syndrome, features 45
- foetal valproate syndrome 177
- functional MRI (fMRI)
 - amygdala activation 30
- future and unanswered questions
 - anxiety and depression disorder 260–261
- gender differences, PTSD 61–64
 - assessment and phenomenology 80
 - biological factors 83–84

271 Index

- cognitive factors 82–83
- social and material support 82
- trauma type 80–82
- gender gap
 - gender intensification hypothesis 3–5
 - limitation 5–7
 - fact or artefact 2–3
- generalized anxiety disorder
 - clinical course 64–65
 - comorbidity 65
- genetic counselling, BD 188
- genetic variable, risk factor/aetiology 141
- Geriatric Depression Scale (GDS) 252, 253
- gonadal hormonal influences, depression
 - androgens 120
 - oestrogen 118–120
 - PKC pathway 119
 - progesterone 120
 - receptor modulators (PRMs) 120
- Hamilton Rating Scale for Depression 252
- help-seeking artefact, gender gap 2
- herbal remedies and supplements
 - St John’s wort 177–178
- hormonal factor, risk factor/aetiology
 - 141–142
- hormone therapy, mood and menopause 224
- hypnotics 171
- incidence and prevalence, domestic violence 93
- induced menopause 213
- interpersonal psychotherapy (IPT) 148, 257
- involutional melancholia 129, 212
- lamotrigine 175, 196, 203
- late reproductive phase 213
 - see also* premenopause
- lithium
 - BD management in pregnancy
 - fetal and neonatal effect 193
 - therapy, during pregnancy and delivery 193–194
- longitudinal course
 - borderline personality disorders and temporal stability 26–27
- longitudinal studies
 - mood and menopause
 - Affectometer 233
 - Melbourne Women’s Midlife Health Project (MWMHP) 233, 234
 - Pennsylvania study 233
 - Seattle Midlife Women’s Health Study 233, 234
- magnetic resonance imaging, structural
 - borderline personality disorder 30
- management
 - anxiety 257–259
 - BD
 - in postpartum period 200–204
 - in pregnancy 191–200
 - depression 252–257
 - postnatal depression (PND) 144–145
 - sleep disturbance
 - benzodiazepines 168–170
 - stress 150
 - women’s mental illness 164
- marital relationship
 - psychosocial factors 143
- menopause, meanings of
 - status 214
 - transition (MT) 213
- menstrual cycle, influences
 - on anxiety symptoms
 - premenstrual dysphoric disorder (PMDD) 68–69
 - PTSD 68
- mental health outcomes, domestic violence 96–99
- minor depression 246
- mirtazapine, antidepressant 174

272 Index

- mood and menopause
 - clinical implications 234
 - cross-sectional studies, results 216–225
 - culture/race 215–216
 - depression and menopause, methodological study 215
 - diagnostic and treatment approaches, perimenopausal women 235–236
 - endocrine changes, menopause 214
 - longitudinal studies 225–234
 - menopause, meanings 213–214
- mood disorder, domestic violence and impact
 - barriers to change 101–104
 - detecting domestic violence 101–102
 - domestic violence identification 102–103
 - disclosing domestic violence 103–104
 - clinical and service recommendations 104–107
 - domestic violence, definition 92–101
 - abuse 93–94
 - effects on children 100–101
 - incidence and prevalence 93
 - mental health outcomes 96–99
 - risk predictors 94–96
 - substance misuse 99–100
- mood disorders
 - emergence of gender gap
 - affective disorders, during adolescence 1–2
 - fact or artefact 2–3
 - gender intensification hypothesis 3–5
 - gender roles and individual differences 7–8
 - pubertal change and interpersonal stressors 9–10
 - pubertal development and diathesis 8–9
 - theories, early adolescence 3–10
 - pubertal influences on vulnerability to depressive disorders 10–13
 - sexual selection and vulnerability 11–13
- mood in pregnancy 138
- mood stabilizers
 - anticonvulsants 176–177
 - lithium 175–176
- motivation factor, depression 246
- N-acetylaspartate (NAA) 30
- nature, PTSD 75–76
- nefazadone, antidepressant 174
- neural tube effects (NTD) 194
- neurobiology 29–31
 - MRS 30
 - MRI 30
 - positron emission tomography 30, 31
- neuroticism 7
- non-pharmacological interventions, anxiety 258–259
- novel anti-psychotics 204
 - fetal and neonatal effects
 - olanzapine 197–198
 - resperidone 198
 - therapy, during pregnancy and delivery 198
- obsessive–compulsive disorder (OCD)
 - anxiety disorder 137, 257
 - clinical course 68
 - comorbidity 67
- oral contraceptives (OCs) 122, 196, 212
- outpatient treatment, substance abuse 50
- panic disorder 59–61, 68, 69, 137
 - clinical course 60
- parental investment theory 11–12
- perimenopausal women
 - diagnostic and treatment approaches
 - breast cancer 236
 - diagnosis, chronic untreated problem 235
 - mood problem 235

273 Index

- percutaneous oestradiol 235–236
 - venlafaxine 236
 - perimenopause 129–130
 - see also* climacteric
 - perinatal anxiety disorders 69–70
 - comorbid anxiety 70
 - depression 70
 - personality
 - psychosocial factors 143
 - personality disorder (PD) 20, 21, 22, 23, 27
 - pharmacological treatment, anxiety and depression
 - antidepressants 171
 - SSRIs 173
 - tricyclic 174
 - agents, others 174
 - anxiolytics 170–171
 - balancing risks with benefits 166–168
 - benzodiazepines 168–170
 - herbal remedies and supplements 177–178
 - hypnotics 171
 - mood stabilizers
 - anticonvulsants 176–177
 - lithium 175–176
 - pharmacotherapy risk 164–165
 - pregnancy and lactation 163
 - therapeutic strategies 166
 - untreated mental illness, risk 165–166
 - pharmacotherapy, risks
 - teratogenicity 164, 165
 - PND 125–128, 139, 150–151
 - polycystic ovaries (PCO) 188
 - positron emission tomography (PET)
 - studies
 - neurobiology 30
 - postpartum period 70, 138, 143, 200
 - postmenopause 213
 - postnatal depression *see* PND
 - postpartum mood disorders
 - blues 138–139
 - perinatal depression 139
 - PND 139–140
 - postpartum period, management of BD
 - anti-convulsants 202–203
 - anti-psychotics 204
 - BDPs 204
 - breastfeeding and medication 201–202
 - lithium 193, 202
 - psychosis 200–201
 - postpartum psychosis 126, 200–201
 - puerperal 140
 - weaning 140
 - treatment 201
 - post-traumatic stress disorder *see* PTSD
 - pregnancy and postpartum period
 - anxiety and mood disorder 136
 - pregnancy planning
 - psychosocial factors 143
 - pregnancy, management of BD
 - anti-convulsants 194–197
 - anti-psychotics 197–198
 - first-generation 197
 - second-generation or novel 197–198
 - benzodiazepines (BDPs) 198–199
 - fetal and neonatal effects 198–199
 - therapy, during pregnancy and delivery 199
 - Carbamazepine
 - ECT 199
 - Lamotrigine
 - lithium 193
 - fetal and neonatal effects 193
 - therapy, during pregnancy and delivery 193–194
 - principle 191–192
 - Topiramate
 - Valproate
- premenopause 213
- premenstrual dysphoric disorder (PMDD) 68–69, 121–122
- premenstrual syndrome (PMS) 121–122
- prevalence, cultures 76–78
- prevention, postpartum depression 146–147
 - primary and secondary
 - anxiety and depression, old age 260

274 Index

- progesterone 84, 120, 123–124
 - receptor modulators (PRMs) 120
- prognosis 259
- propranolol 170–171
- psychological and psychotherapeutic interventions
 - depression 255–257
- psychological development, old age 244–245
- psychological symptom, mood and menopause 212
- psychosocial issues
 - substance abuse 43–44
- PTSD
 - anxiety disorder 98–99
 - battered woman syndrome 99
 - development 78–79
 - gender differences 79–84
 - assessment and phenomenology 80
 - biological factors 83–84
 - cognitive factors 82–83
 - social and material support 82
 - trauma type 80–82
 - nature 75–76
 - prevalence, cultures 76–78
 - treatment 84
 - pharmacotherapy 85–86
 - psychological interventions 84–85
- pubertal influences on vulnerability
 - depression
 - sexual selection and vulnerability 11–13
- pyridoxine 123
- recall artefact, gender gap 2
- residential treatment, substance abuse 51
- resistant, depression 257
- risk and protective factors, anxiety and depression
 - women, in old age
 - precipitating factors 250–251
 - predisposing factors 248–250
 - protective factors 251
- risk predictor, domestic violence 94–96
- selective serotonin reuptake inhibitors (SSRIs) 85, 121–122, 127, 173
- sex difference
 - possible sources
 - biased application, diagnostic criteria 23
 - biased assessment instruments 24
 - biased diagnostic construct 22
 - biased sampling 23–24
 - biased thresholds, diagnosis 23
- sleep deprivation
 - circadian rhythm dysregulation 149
- sleep regulation
 - risk factor/aetiology 142
- social phobia
 - clinical course 66
 - comorbidity 66
- social support
 - psychosocial factors 143–144
- social-risk hypothesis 10
- socialisation experience 3
- special needs, women
 - pregnant women 52
 - court proceedings 53
 - sex industry 52–53
 - women with children 52
- specific life cycle, of depressive disorders in women
 - depression
 - abortion and miscarriage 124–125
 - hormonal contraception 122–124
 - perimenopause and menopause 129–130
 - and infertility, in women, 128–129
 - and pregnancy 125
 - antidepressants (AD) 125
 - PND 125–128
 - premenstrual dysphoric disorder (PMDD) 121–122
- St John's wort 177–178
- substance misuse
 - and domestic violence 99–100

275 Index

substance use and abuse, women	treatment issues, mother
life phase approach	biological 148
middle age and later life 46	ECT 149, 201
reproductive years 44–45	pharmacological/hormonal
youth and adolescence 44	interventions 148–149
gender differences 39–41	sleep deprivation 149
course worse, women 42–44	psychosocial 147–148
domestic violence 99–100	treatment issues, partners and couples
epidemiology and clinical issues 39–44	couple issues 150
comorbidity and long-term course	PND
41–42	in lesbian mothers 150–151
gender differences 39–41	in men 150
life phase approach 44–46	treatment, drug and alcohol problems in
middle age and later life 46	women
reproductive years 44–45	engagement in treatment 48–49
youth and adolescence 44	heterogeneity 53
treatment, drug and alcohol problems	pharmacotherapy maintenance
46–53	treatment, women 52
engagement in treatment 48–49	retention in treatment 49–50
heterogeneity 53	specialist treatment services 50–51
pharmacotherapy maintenance	outpatient treatment 50
treatment 52	residential treatment 51
retention in treatment 49–50	barriers, women 46–48
special needs 52–53	needs 48
specialist treatment 50–51	treatment, PTSD
treatment barriers 46–48	pharmacotherapy 85–86
treatment needs 48	psychological interventions 84–85
temporal stability	treatment principles, depression 253–254
personality disorders (PD) 26–27	tricyclic antidepressants 171, 172, 174
therapeutic strategies	tamoxifen
anxiety and depression	PKC inhibitor 119
during pregnancy and lactation 166	unipolar depression 1, 8, 117, 186,
topiramate 196–197, 203	187, 245
trauma and PTSD	untreated mental illness, risks 106, 141,
development 78–79	165–166, 167
treatment issues	valproate 176–177, 194–195, 202–203
anxiety and mood disorders	venlafaxine 172, 174, 236, 255
child 151–152	
inpatient units 149–150	zolpidem 171
mother 147–149	zopiclone 171
partners and couples 150–151	